(Q43601445)

25 November 2017

Long-term outcome of patients who receive ketamine during research (English)

1 reference

25 November 2017

6

Tamminga CA

1 reference

25 November 2017

Lahti AC

1

1 reference

25 November 2017

Warfel D

2

1 reference

25 November 2017

Michaelidis T

3

1 reference

25 November 2017

Weiler MA

4

1 reference

25 November 2017

Frey K

5

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

25 November 2017

Biological Psychiatry

1 reference

25 November 2017

49

1 reference

25 November 2017

10

1 reference

25 November 2017

869-875

1 reference

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

The risk of medication-free research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

The schizophrenia ketamine challenge study debate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Recent advances in the phencyclidine model of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Does a four-week delay in the introduction of medication alter the course of functional psychosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Ketamine activates psychosis and alters limbic blood flow in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Absence of ketamine effects on memory and other cognitive functions in schizophrenia patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

The effects of a sub-anaesthetic dose of ketamine on human selective attention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Ketamine: an update on the first twenty-five years of clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Are there long-term effects of ketamine on the central nervous system?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Ketamine effects on eye movements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Ketamine--its pharmacology and therapeutic uses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

Research in schizophrenia and the discontinuation of antipsychotic medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901037-4

10.1016/S0006-3223(00)01037-4

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference